|
業務類別
|
Biotechnology |
|
業務概覽
|
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. |
| 公司地址
| 433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432 |
| 電話號碼
| +1 561 589-7020 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.enterothera.com |
| 員工數量
| 2 |
| Dr. Jack Syage, PhD |
Director and President |
-- |
01/05/2026 |
| Mr. Jason Sawyer |
Chief Executive Officer and Director |
-- |
01/05/2026 |
| Ms. Anna Skowron, C.A.,C.P.A. |
Interim Chief Financial Officer and Principal Accounting Officer |
-- |
01/05/2026 |
|
|
| Mr. Edward J. Borkowski |
Lead Independent Director |
01/05/2026 |
| Dr. Jack Syage, PhD |
Director and President |
01/05/2026 |
| Mr. Manpreet Uppal |
Director |
01/05/2026 |
| Mr. Jason Sawyer |
Chief Executive Officer and Director |
01/05/2026 |
| Mr. Geordan Pursglove |
Director |
01/05/2026 |
|
|
|
|
